Literature DB >> 28277330

PharmGKB summary: voriconazole pathway, pharmacokinetics.

Julia M Barbarino1, Aniwaa Owusu Obeng, Teri E Klein, Russ B Altman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28277330      PMCID： PMC5405706          DOI： 10.1097/FPC.0000000000000276

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  56 in total

1.  A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine.

Authors:  Mirte M Malingré; Peggy C R Godschalk; Saskia K Klein
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

2.  Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.

Authors:  Brad Moriyama; Oluwaseun Falade-Nwulia; Janice Leung; Scott R Penzak; Caroline JJingo; Xuan Huang; Stacey A Henning; Wyndham H Wilson; Thomas J Walsh
Journal:  Mycoses       Date:  2011-05-25       Impact factor: 4.377

3.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.

Authors:  B Moriyama; A Owusu Obeng; J Barbarino; S R Penzak; S A Henning; S A Scott; Jag Agúndez; J R Wingard; H L McLeod; T E Klein; S J Cross; K E Caudle; T J Walsh
Journal:  Clin Pharmacol Ther       Date:  2017-04-18       Impact factor: 6.875

4.  Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes.

Authors:  Karine Bourcier; Ruth Hyland; Sarah Kempshall; Russell Jones; Jacqueline Maximilien; Nicola Irvine; Barry Jones
Journal:  Drug Metab Dispos       Date:  2010-03-19       Impact factor: 3.922

5.  PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.

Authors:  Stuart A Scott; Katrin Sangkuhl; Alan R Shuldiner; Jean-Sébastien Hulot; Caroline F Thorn; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-02       Impact factor: 2.089

6.  Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes.

Authors:  Kazuaki Matsumoto; Kazuro Ikawa; Kazuko Abematsu; Naoko Fukunaga; Kentaro Nishida; Tomohide Fukamizu; Yoshihiro Shimodozono; Norifumi Morikawa; Yasuo Takeda; Katsushi Yamada
Journal:  Int J Antimicrob Agents       Date:  2009-03-03       Impact factor: 5.283

7.  Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes.

Authors:  Souzan B Yanni; Pieter P Annaert; Patrick Augustijns; Arlene Bridges; Yan Gao; Daniel K Benjamin; Dhiren R Thakker
Journal:  Drug Metab Dispos       Date:  2008-03-24       Impact factor: 3.922

Review 8.  CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?

Authors:  Aniwaa Owusu Obeng; Eric F Egelund; Abdullah Alsultan; Charles A Peloquin; Julie A Johnson
Journal:  Pharmacotherapy       Date:  2014-02-07       Impact factor: 4.705

9.  Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Authors:  S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2013-05-22       Impact factor: 6.875

10.  Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity.

Authors:  Yassine Bouatou; Caroline Flora Samer; Kuntheavy Roseline Ing Lorenzini; Youssef Daali; Samira Daou; Marc Fathi; Michela Rebsamen; Jules Desmeules; Alexandra Calmy; Monica Escher
Journal:  AIDS Res Ther       Date:  2014-08-04       Impact factor: 2.250
View more
  6 in total

1.  PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics.

Authors:  Maria Alvarellos; Chantal Guillemette; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2018-05       Impact factor: 2.089

2.  Applying Pharmacogenomics to Antifungal Selection and Dosing: Are We There Yet?

Authors:  Matthew A Miller; Yee Ming Lee
Journal:  Curr Fungal Infect Rep       Date:  2020-01-16

Review 3.  Review of Intraocular Pharmacokinetics of Anti-Infectives Commonly Used in the Treatment of Infectious Endophthalmitis.

Authors:  Andrea Luaces-Rodríguez; Miguel González-Barcia; María José Blanco-Teijeiro; María Gil-Martínez; Francisco Gonzalez; Francisco Gómez-Ulla; María-Jesús Lamas; Francisco-Javier Otero-Espinar; Anxo Fernández-Ferreiro
Journal:  Pharmaceutics       Date:  2018-05-29       Impact factor: 6.321

4.  Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization.

Authors:  Yahui Zhang; Sixuan Zhao; Chuhui Wang; Pengxiang Zhou; Suodi Zhai
Journal:  Front Pharmacol       Date:  2021-03-17       Impact factor: 5.810

5.  CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation.

Authors:  Takuto Takahashi; Maryam A Mohamud; Angela R Smith; Pamala A Jacobson; Mutaz M Jaber; Abeer F Alharbi; James Fisher; Mark N Kirstein
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

6.  A potential implication of UDP-glucuronosyltransferase 2B10 in the detoxification of drugs used in pediatric hematopoietic stem cell transplantation setting: an in silico investigation.

Authors:  Shannon Robin; Khalil Ben Hassine; Tiago Nava; Chakradhara Rao S Uppugunduri; Marc Ansari; Jayaraman Muthukumaran; Simona Jurkovic Mlakar; Maja Krajinovic
Journal:  BMC Mol Cell Biol       Date:  2022-01-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.